Kairos Pharma, Ltd. (KAPA)

Kairos Pharma Statistics

Total Valuation

Kairos Pharma has a market cap or net worth of $11.97 million. The enterprise value is $6.63 million.

Market Cap	11.97M
Enterprise Value	6.63M

Important Dates

The next estimated earnings date is Tuesday, April 14, 2026, after market close.

Earnings Date	Apr 14, 2026
Ex-Dividend Date	n/a

Share Statistics

Kairos Pharma has 20.82 million shares outstanding. The number of shares has increased by 55.64% in one year.

Current Share Class	20.82M
Shares Outstanding	20.82M
Shares Change (YoY)	+55.64%
Shares Change (QoQ)	+17.39%
Owned by Insiders (%)	37.55%
Owned by Institutions (%)	8.36%
Float	11.83M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	1.67
P/TBV Ratio	1.61
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 16.56

Current Ratio	16.56
Quick Ratio	13.87
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -92.07% and return on invested capital (ROIC) is -62.88%.

Return on Equity (ROE)	-92.07%
Return on Assets (ROA)	-53.59%
Return on Invested Capital (ROIC)	-62.88%
Return on Capital Employed (ROCE)	-73.11%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	n/a
Profits Per Employee	-$1.69M
Employee Count	3
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -38.85% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-38.85%
50-Day Moving Average	0.67
200-Day Moving Average	0.90
Relative Strength Index (RSI)	41.53
Average Volume (20 Days)	1,306,092

Short Selling Information

The latest short interest is 1.27 million, so 6.12% of the outstanding shares have been sold short.

Short Interest	1.27M
Short Previous Month	144,124
Short % of Shares Out	6.12%
Short % of Float	10.77%
Short Ratio (days to cover)	1.15

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-5.60M
Pretax Income	-5.06M
Net Income	-5.06M
EBITDA	-5.44M
EBIT	-5.60M
Earnings Per Share (EPS)	-$0.31

Balance Sheet

The company has $5.58 million in cash and n/a in debt, with a net cash position of $5.58 million or $0.27 per share.

Cash & Cash Equivalents	5.58M
Total Debt	n/a
Net Cash	5.58M
Net Cash Per Share	$0.27
Equity (Book Value)	7.66M
Book Value Per Share	0.37
Working Capital	6.25M

Cash Flow

Operating Cash Flow	-4.16M
Capital Expenditures	n/a
Depreciation & Amortization	160,000
Net Borrowing	3.46M
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Kairos Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-55.64%
Shareholder Yield	-55.64%
Earnings Yield	-41.49%
FCF Yield	n/a

Analyst Forecast

The average price target for Kairos Pharma is $8.33, which is 1,349.20% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$8.33
Price Target Difference	1,349.20%
Analyst Consensus	Strong Buy
Analyst Count	3
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2